GA-A

GA-A is a novel small molecule hybrid inhibitor designed to target multiple myeloma (MM). It is synthesized by coupling an aralkyl carboxylic acid moiety, which inhibits the anti-apoptotic protein Mcl-1, with gambogic acid, a natural compound known to inhibit the chemokine receptor CXCR4. By dual-targeting these pathways, GA-A aims to overcome resistance to standard therapies like bortezomib and eliminate MM stem-like cells. Preclinical studies presented at AACR 2024 demonstrate that GA-A suppresses CXCR4 and Mcl-1 expression, induces apoptosis in CD138- stem-like populations, and activates proinflammatory cytokines such as GM-CSF, IFN-gamma, IL-2, and IL-12, potentially stimulating an immune response against the tumor.